Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 466 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR 10 Ways the Inflation Reduction Act will Impact Cancer Care August 18, 2022 What to Know About Returning to Work After Cancer Treatment: An... February 15, 2024 PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for... March 28, 2024 Girl’s New College Dorm Has Perfect View Of The Hospital Room... September 30, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Lorlatinib Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors Crazy Bride Called Off Her Wedding Because Her Guests Refused To...
